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Abstract  
BACKGROUND: Keratinocyte cancers are malignant diseases with a broad incidence of spread which tends to 
increase during the last couple of decades. The solar radiation plays a dominant role in the occurrence of BCC, 
but certain genetic phenotypes appear to be risky from an etiological point of view. Metatypical basal cell 
carcinoma (MTBCC) is a rare variant of BCC which combines the clinical and histological characteristics of BCC 
and SCC. Clinically they are indistinguishable from the conventional BCC, and only the histological examination 
can differentiate them. The MTBCC is a histological subtype which is considered more aggressive due to its ability 
to produce local recurrences or distant metastases. 
CASE REPORT: We present a 44-year old patient with multiple BCCs disseminated on the face and body. The 
biopsy established mixed type histology: three metatypical and four solid BCCs. The lesions were removed via 
elliptical excision with a field of operational security of 0.5 cm in all directions. 
CONCLUSIONS: The eruptive (multiple) BCCs are a challenge about the choice of a therapy option. This is 
because clinically completely identical tumours show different histopathological characteristics, namely those with 
a tendency to metastasise. Having in mind one of the hypotheses of metatypical BCC emergence - the improper 
or inadequate radiotherapy (as a choice of therapy) could trigger the transition of a conventional tumour to a 
metastasising one, the surgical treatment appears to be the most secure treatment method. 
 
 
 
 
 
Introduction 
 
The BCC is the most common malignant skin 
disease [1]. The solar radiation, skin phototype 1, as 
well as certain genetic diseases (albinism, xeroderma 
pigmentosa, Bazex's syndrome and Gorlin's 
syndrome), are considered as main risk factors about 
BCC development [1][2]. From the few existing 
histological subtypes of BCC, the ones of particular 
interest are the metatypical MTBCCs which combine 
the clinical and histological characteristics of BCC and 
SCC [3]. MTBCC is regarded as the most aggressive 
due to its ability to cause local recurrences and distant 
metastases [4]. It is believed that the 
inappropriate/inadequate radiotherapy of non-
melanoma skin tumours could lead to their transition 
to a metastatic metatypical variant of BCC [5]. Due to 
this reason, the first choice of BCC treatment should 
be the surgical removal [6]. 
 
 
Case report 
 
A 44-year old man is presented; phototype 1 
and many years exposure to solar radiation. 
Anamnestic data showed 25 years old state of the 
disseminated lesions on the head and body. Multiple 
skin lesions of different location and size were seen 
on examination. In the area of shoulders, face, chest 
and nape were observed ulcerative lesions (Figure 
Case Report  
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
1436                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
1a-f) while on the back were set erythema plaques 
covered with crusty exudate (Figure 2c).  
 
Figure 1: a-f) Multiple BCC with relative similar clinical appearance. 
Clinical observation during the first medical examination 
 
Seven of the lesions were removed by 
elliptical excision with a field of operational security of 
0.5 cm in all directions (Figure 2a-d). The histological 
examination showed a mixed histological picture: 
three multicentric BCCs with clean resection lines and 
four solid BCCs with free resection lines.  
 
Figure 2: a-d) Clinical status postoperatively 
 
By the histological data was set the diagnosis 
of metatypical BCCs for two of the surgically removed 
lesions (Figures 3a-c; 4a-c). 
 
 
Figure 3: a-c) Metatypical basal cell carcinoma with typical 
histopathological features 
The clinical examination did not find the 
presence of lymphadenopathy, the lung and heart 
radiography detected no focal and infiltrative changes, 
the ultrasound of cervical, axillary and inguinal area 
did not register enlarged lymph nodes, paraclinical 
data-with no specificities.  
 
Figure 4: a-c) Metatypical basal cell carcinoma with typical 
histopathological features 
 
 
Discussion 
 
The basal cell carcinoma is the neoplasia with 
the highest incidence rate among the population 
worldwide which exhibits the trend to increase in the 
last couple of decades with an average 10% per 
annum [1]. The solar radiation is considered as the 
main etiological factor for BCC occurrence [2]. The 
other risk factors for the development of basal cell 
carcinoma include skin phototype 1, blond or red hair, 
blue or green eyes, sunburnt from childhood, family 
history of cancer or immunosuppressive treatment [1]. 
Certain genetic diseases are also associated with a 
higher risk of basal cell carcinoma development, 
namely: albinism, xeroderma pigmentosa, Bazex's 
syndrome and Gorlin's syndrome [1]. Interesting are 
two phenotypes: 1) patients with clusters of BCC 
which have between two and five clinically manifested 
basal cell carcinoma, i.e. multiple presentation 
phenotypes and 2) patients with basal cell carcinoma 
on the trunk [7]. In both cases is considered that a 
genetic predisposition exists [7]. The patients with 
BCC on the trunk are interesting because it is 
believed that the development of basal cell carcinoma 
in this localisation is mediated via different 
mechanisms in comparison with those that are 
involved in affecting other parts of the body [8]. Male 
gender, young age and the number of sunburns are 
regarded as risk factors for the development of BCC 
on the trunk [9]. The identification of genes that are 
linked to the basal cell carcinoma development has 
great importance for better understanding of their 
pathogenesis [10]. According to recent research, the 
changed activation of the Hedgehog pathway is a key 
step in the carcinogenesis of BCC [10]. It has been 
established that mutations in the genes PTCH1, SMO 
as well as LATS1 and PTPN14, from the Hippo-YAP 
pathway are linked to BCC development [10].  
The patients with BCC show differences in the 
tumours’ location on the body, the lesions’ number as 
well as the histological subtype [11]. Histologically the 
BCC is divided into nodular, superficial, morpheaform, 
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infiltrating, metatypic, and fibroepithelioma of Pinkus 
[12]. The metatypical BCC is a histological variant 
which combines the histological characteristics of 
BCC and SCC [3]. MTBCC is divided into two 
histological subtypes: intermediate and mixed [3]. 
Clinically the metatypical BCC cannot be 
distinguished from the other variants, and only the 
histological examination could differentiate them [13]. 
It is believed that MTBCC shows more aggressive 
behaviour and apart from local recurrences could also 
lead to distant metastases [14]. The available 
literature data points that the metastatic potential of 
MTBCC is around 7.4% [15]. BCC most commonly 
metastasise via lymphogenic or haematogenic 
pathway affecting lymph nodes, lungs or bones [16]. 
This requires the necessity of a more careful 
approach and specific treatment of the metatypical 
BCC.  
The standard approach of treatment of basal 
cell carcinoma is surgical excision, curettage, 
curettage with electrodesiccation, Mohs micrographic 
surgery and radiotherapy [17]. Superficial radiation 
therapy is an alternative treatment of non-melanoma 
skin tumours, such as BCC and SCC [17]. In that case 
are considered tumour size, location, histological 
subtype and the patient’s age; the often applied 
radiotherapy regimen is of a total dose of 4,500cGY 
(300cGy/fractionx15 fractions) [17]. However, 
according to clinical research data, few factors are 
risky for metatypical BCC development: 1) history of 
BCC for many years, 2) no response to conventional 
methods of treatment and 3) conducted radiotherapy 
in the past [5]. Because the radiation therapy is a risk 
factor for transitioning to the metastatic variant of BCC 
(MTBCC), the full surgical excision of the basal cell 
carcinoma is of utmost importance and should be the 
first choice of the treatment method of those 
carcinoma [5] [6]. The recommended margins of 
surgical security, which provide for up to 96% optimal 
elimination of BCC, are on average 4 mm (3 mm for 
the face and 5mm for the other body parts) [15]. It is 
necessary that patients with BCC, especially stage T3 
or T4, as well as histologically confirmed MTBCC, to 
be monitored in the course of 10 or more years for the 
presence of local recurrences or distant metastases 
[5] [6]. 
In conclusion, metatypical BCC is an 
aggressive variant of BCC which is associated with a 
higher risk of local recurrences and possibility of 
developing distant metastases. The diagnosis of 
MTBCC could be determined only by histological 
examination. Because radiotherapy of skin tumours 
poses a risk of transitioning to metatypical BCC, 
surgical treatment of that carcinoma should be a 
priority. 
The surgical approach is the adequate one as 
clinically often there are no differences, but often the 
histology is different. On that basis, BCC could be 
determined, analogically to other diseases in the 
dermatology, like a chameleon.  
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